Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SAGE Stock Forecast 2025-2026
$6.61
Current Price
$418.93M
Market Cap
Buy 3
Hold 15
Sell 1
Wall St Analyst Ratings
Distance to SAGE Price Targets
+81.5%
To High Target of $12.00
+21.0%
To Median Target of $8.00
-24.4%
To Low Target of $5.00
SAGE Price Momentum
-4.1%
1 Week Change
-15.1%
1 Month Change
-43.9%
1 Year Change
+21.7%
Year-to-Date Change
-50.9%
From 52W High of $13.47
+43.1%
From 52W Low of $4.62
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Sage (SAGE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SAGE and similar high-potential opportunities.
Latest SAGE Stock Price Targets & Analyst Predictions
Based on our analysis of 29 Wall Street analysts, SAGE has a neutral consensus with a median price target of $8.00 (ranging from $5.00 to $12.00). The overall analyst rating is Buy (6.2/10). Currently trading at $6.61, the median forecast implies a 21.0% upside. This outlook is supported by 3 Buy, 15 Hold, and 1 Sell ratings.
The most optimistic forecast comes from George Farmer at Scotiabank, projecting a 81.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SAGE Analyst Ratings
3
Buy
15
Hold
1
Sell
SAGE Price Target Range
Low
$5.00
Average
$8.00
High
$12.00
Current: $6.61
Latest SAGE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SAGE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 30, 2025 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Apr 25, 2025 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Feb 12, 2025 | Scotiabank | George Farmer | Sector Outperform | Maintains | $12.00 |
| Feb 12, 2025 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Feb 12, 2025 | Canaccord Genuity | Sumant Kulkarni | Hold | Maintains | $8.00 |
| Feb 12, 2025 | Wedbush | Laura Chico | Neutral | Reiterates | $6.00 |
| Feb 12, 2025 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $12.00 |
| Jan 2, 2025 | Piper Sandler | David Amsellem | Overweight | Maintains | $9.00 |
| Dec 16, 2024 | Stifel | Paul Matteis | Hold | Maintains | $6.00 |
| Nov 21, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Upgrade | $4.00 |
| Nov 21, 2024 | TD Cowen | Ritu Baral | Hold | Maintains | $9.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $14.00 |
| Nov 20, 2024 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Oct 30, 2024 | Truist Securities | Joon Lee | Hold | Maintains | $8.00 |
| Oct 30, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Reiterates | $26.00 |
| Oct 30, 2024 | Oppenheimer | Jay Olson | Perform | Maintains | $8.00 |
| Oct 30, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Maintains | $14.00 |
| Oct 30, 2024 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Oct 30, 2024 | Scotiabank | George Farmer | Sector Outperform | Maintains | $14.00 |
| Oct 17, 2024 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
Sage Therapeutics Inc. (SAGE) Competitors
The following stocks are similar to Sage based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SAGE
Sage Therapeutics
mkt cap
413.92M
Sage Therapeutics Inc. (SAGE) Financial Data
Sage Therapeutics Inc. has a market capitalization of $418.93M with a P/E ratio of -1.0x. The company generates $47.40M in trailing twelve-month revenue with a 77.1% profit margin.
Revenue growth is +78.0% quarter-over-quarter, while maintaining an operating margin of -476.0% and return on equity of -63.5%.
Valuation Metrics
Market Cap
$418.93M
Enterprise Value
$13.82M
P/E Ratio
-1.0x
PEG Ratio
-1.6x
Price/Sales
8.8x
Growth & Margins
Revenue Growth (YoY)
+78.0%
Gross Margin
+95.3%
Operating Margin
-476.0%
Net Margin
+77.1%
EPS Growth
+78.0%
Financial Health
Cash/Price Ratio
+102.4%
Current Ratio
9.1x
Debt/Equity
2.9x
ROE
-63.5%
ROA
-36.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Sage Therapeutics Inc. (SAGE) Business Model
About Sage Therapeutics Inc.
What They Do
Develops novel medicines for brain disorders.
Business Model
The company focuses on advancing treatments for psychiatric and neurological conditions, generating revenue through the development and commercialization of innovative therapies. By targeting significant unmet medical needs in mental health, Sage Therapeutics aims to capture market share in a growing biopharmaceutical sector.
Additional Information
Headquartered in Cambridge, Massachusetts, Sage Therapeutics is recognized for its research on GABA and NMDA receptors, which are crucial for neurological health. The company's commitment to scientific innovation positions it as a key player in the biopharma market, potentially transforming patient care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
353
CEO
Mr. Barry E. Greene
Country
United States
IPO Year
2014
Website
www.sagerx.comSage Therapeutics Inc. (SAGE) Latest News & Analysis
Latest News
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Sage Therapeutics investors who bought shares before April 12, 2021. More information is available at bgandg.com/SAGE.
Why It Matters
The investigation into Sage Therapeutics may indicate potential legal issues or financial risks that could affect the company's stock performance, influencing investor sentiment and decisions.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Sage Therapeutics (NASDAQ:SAGE) investors who purchased securities before April 12, 2021.
Why It Matters
The investigation into Sage Therapeutics may indicate potential legal issues or financial risks, affecting stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Sage Therapeutics (NASDAQ:SAGE) who purchased shares before April 12, 2021.
Why It Matters
The investigation into Sage Therapeutics may indicate potential legal issues or financial troubles, which could impact stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Sage Therapeutics (NASDAQ:SAGE) who purchased securities before April 12, 2021.
Why It Matters
The investigation into Sage Therapeutics may indicate potential legal issues or financial instability, affecting stock value and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Sage Therapeutics (NASDAQ:SAGE) who bought shares before April 12, 2021.
Why It Matters
The investigation into Sage Therapeutics may indicate potential legal issues or financial risks, affecting stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Sage Therapeutics (NASDAQ:SAGE) who purchased securities before April 12, 2021.
Why It Matters
The investigation into Sage Therapeutics may indicate potential legal issues or financial risks, potentially affecting stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About SAGE Stock
What is Sage Therapeutics Inc.'s (SAGE) stock forecast for 2025?
Based on our analysis of 29 Wall Street analysts, Sage Therapeutics Inc. (SAGE) has a median price target of $8.00. The highest price target is $12.00 and the lowest is $5.00.
Is SAGE stock a good investment in 2025?
According to current analyst ratings, SAGE has 3 Buy ratings, 15 Hold ratings, and 1 Sell ratings. The stock is currently trading at $6.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SAGE stock?
Wall Street analysts predict SAGE stock could reach $8.00 in the next 12 months. This represents a 21.0% increase from the current price of $6.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sage Therapeutics Inc.'s business model?
The company focuses on advancing treatments for psychiatric and neurological conditions, generating revenue through the development and commercialization of innovative therapies. By targeting significant unmet medical needs in mental health, Sage Therapeutics aims to capture market share in a growing biopharmaceutical sector.
What is the highest forecasted price for SAGE Sage Therapeutics Inc.?
The highest price target for SAGE is $12.00 from George Farmer at Scotiabank, which represents a 81.5% increase from the current price of $6.61.
What is the lowest forecasted price for SAGE Sage Therapeutics Inc.?
The lowest price target for SAGE is $5.00 from at , which represents a -24.4% decrease from the current price of $6.61.
What is the overall SAGE consensus from analysts for Sage Therapeutics Inc.?
The overall analyst consensus for SAGE is neutral. Out of 29 Wall Street analysts, 3 rate it as Buy, 15 as Hold, and 1 as Sell, with a median price target of $8.00.
How accurate are SAGE stock price projections?
Stock price projections, including those for Sage Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 10:07 PM UTC